| London Stock Exchange: GDR
Genedrive plc is an established Biotechnology Company with headquarters in Manchester UK, and facilities in the US. Established initially as Epistem Ltd in 2000 by Prof. Chris Potten and Dr. Cath Booth, Epistem's scientific foundation was based on several decades of ground-breaking stem cell research by Prof. Potten. Based at the Paterson Institute for Cancer Research at the Christie Hospital and the University of Manchester, UK, Prof. Potten identified and characterised the location and behaviour of stem cells in the intestine, skin, hair follicle and breast. To support this revolutionary research, the team developed powerful models and assays to understand the controls of epithelial cell turnover and methods to quantify tissue damage, regeneration and metaplasia. As a result of increasing demand from pharmaceutical and biotechnology companies for access to these models, Prof. Potten and Dr. Booth formed Epistem.
In 2001, Epistem moved into the current purpose-built facilities at the heart of the vibrant scientific, medical and academic community of Manchester. In 2014, a second laboratory facility was opened in Baltimore, MD, to provide local support to Epistem's customers in the USA. The addition of sales offices in Massachusetts and Maryland continue to support a growing demand for services and the expansion of Epistem within the USA.
Epistem floated on the London AIM market in April 2007 trading as Epistem Holdings Plc (LSE: EHP). A subsequent change to genedrive plc occurred in 2016. genedrive plc operates a combined business model integrating the strengths of three complementary divisions.